Literature DB >> 7916148

Transfection of tissue transglutaminase into a highly malignant hamster fibrosarcoma leads to a reduced incidence of primary tumour growth.

T S Johnson1, C R Knight, S el-Alaoui, S Mian, R C Rees, V Gentile, P J Davies, M Griffin.   

Abstract

Reduced expression of the tissue transglutaminase in both murine and human tumours has been consistently associated with tumour growth and progression. To investigate the functional effects of transglutaminase expression we have transfected a constitutive human tissue transglutaminase expression construct into a highly malignant hamster fibrosarcoma cell line Met B. Met B clones expressing the exogenous tissue transglutaminase exhibited a reduced incidence of primary tumour formation and an increased adherence to tissue culture plastic and fibronectin coated surfaces when compared to transfected and non transfected control cells. Transglutaminase transfected clones exhibited no significant differences in their growth rates measured in vitro, cell morphology or levels of spontaneous apoptosis measured by the determination of detergent insoluble apoptotic envelopes. The data demonstrates a suppressive effect of tissue transglutaminase on tumour growth and confirms its importance in the phenotypic changes associated with the cancer process.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7916148

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  13 in total

1.  Role of transglutaminase II in retinoic acid-induced activation of RhoA-associated kinase-2.

Authors:  U S Singh; M T Kunar; Y L Kao; K M Baker
Journal:  EMBO J       Date:  2001-05-15       Impact factor: 11.598

2.  GPR56, an atypical G protein-coupled receptor, binds tissue transglutaminase, TG2, and inhibits melanoma tumor growth and metastasis.

Authors:  Lei Xu; Shahinoor Begum; Jeremy D Hearn; Richard O Hynes
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-06       Impact factor: 11.205

3.  The cell cycle and induction of apoptosis in a hamster fibrosarcoma cell line treated with anti-cancer drugs: its importance to solid tumour chemotherapy.

Authors:  S el Alaoui; J Lawry; M Griffin
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

4.  The role of transglutaminase in the rat subtotal nephrectomy model of renal fibrosis.

Authors:  T S Johnson; M Griffin; G L Thomas; J Skill; A Cox; B Yang; B Nicholas; P J Birckbichler; C Muchaneta-Kubara; A Meguid El Nahas
Journal:  J Clin Invest       Date:  1997-06-15       Impact factor: 14.808

5.  The transglutaminase 2 gene is aberrantly hypermethylated in glioma.

Authors:  Lisa M Dyer; Kevin P Schooler; Lingbao Ai; Corinne Klop; Jingxin Qiu; Keith D Robertson; Kevin D Brown
Journal:  J Neurooncol       Date:  2010-07-03       Impact factor: 4.130

6.  Induction of tissue transglutaminase by dexamethasone: its correlation to receptor number and transglutaminase-mediated cell death in a series of malignant hamster fibrosarcomas.

Authors:  T S Johnson; C I Scholfield; J Parry; M Griffin
Journal:  Biochem J       Date:  1998-04-01       Impact factor: 3.857

7.  Tissue specific and androgen-regulated expression of human prostate-specific transglutaminase.

Authors:  H J Dubbink; N S Verkaik; P W Faber; J Trapman; F H Schröder; J C Romijn
Journal:  Biochem J       Date:  1996-05-01       Impact factor: 3.857

Review 8.  Transglutaminases: nature's biological glues.

Authors:  Martin Griffin; Rita Casadio; Carlo M Bergamini
Journal:  Biochem J       Date:  2002-12-01       Impact factor: 3.857

9.  Measurement of tissue transglutaminase activity in a permeabilized cell system: its regulation by Ca2+ and nucleotides.

Authors:  P A Smethurst; M Griffin
Journal:  Biochem J       Date:  1996-02-01       Impact factor: 3.857

10.  Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin.

Authors:  S S Akimov; D Krylov; L F Fleischman; A M Belkin
Journal:  J Cell Biol       Date:  2000-02-21       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.